MNPR
Monopar Therapeutics Inc

3,324
Mkt Cap
$366.24M
Volume
74,301.00
52W High
$105.00
52W Low
$26.06
PE Ratio
-15.94
MNPR Fundamentals
Price
$53.08
Prev Close
$54.81
Open
$53.27
50D MA
$63.81
Beta
1.48
Avg. Volume
317,658.35
EPS (Annual)
-$4.11
P/B
2.58
Rev/Employee
$0.00
$23.17
Loading...
Loading...
News
all
press releases
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Buy" from Brokerages
Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have received an average rating of "Buy" from the thirteen ratings firms that are presently covering the firm, Marketbeat reports...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research
BTIG Research reaffirmed a "buy" rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday...
MarketBeat·7d ago
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 1,056,017 shares, a...
MarketBeat·1mo ago
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) CFO Quan Anh Vu Acquires 1,500 Shares
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CFO Quan Anh Vu bought 1,500 shares of Monopar Therapeutics stock in a transaction dated Friday, December 26th. The stock was acquired at an...
MarketBeat·2mo ago
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) CFO Purchases 1,500 Shares
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CFO Quan Anh Vu purchased 1,500 shares of the business's stock in a transaction dated Friday, December 26th. The shares were purchased at an...
MarketBeat·2mo ago
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest...
MarketBeat·2mo ago
News Placeholder
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Zacks·2mo ago
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has earned a consensus recommendation of "Buy" from the thirteen brokerages that are covering the firm, Marketbeat reports. One analyst has...
MarketBeat·3mo ago
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·3mo ago
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.3% - Should You Buy?
Monopar Therapeutics (NASDAQ:MNPR) Trading Up 6.3% - Still a Buy...
MarketBeat·3mo ago
<
1
2
...
>

Latest MNPR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.